Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance

Oncogene

Volumn 31, Issue 1, 2012, Pages 39-47

  Bergamaschi, A ^a   Katzenellenbogen, B S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

14 3 3 ; breast cancer; endocrine resistance; miR 451; tamoxifen; tumor suppressor

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MICRORNA; MICRORNA 451; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN 14 3 3; PROTEIN 14 3 3 ZETA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CELL STRAIN MCF 7; CELL SURVIVAL; ENZYME ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

14-3-3 PROTEINS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 7; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICRORNAS; RALOXIFENE; RECEPTOR, ERBB-2; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84855339741     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.223     Document Type: Article

References (42)

1. Allgood VE, Zhang Y, O'Malley BW, Weigel NL. (1997). Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus-mediated procedure for high-efficiency DNA transfer. Biochemistry 36: 224-232. (Pubitemid 27024696)
2. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al. (2004). Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279: 25549-25561. (Pubitemid 38756815)
3. Arpino G, Wiechmann L, Osborne CK, Schiff R. (2008). Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233. (Pubitemid 351519691)
4. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X et al. (2009). microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 15: 2281-2290.
5. Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
6. Bergamaschi A, Frasor J, Kieser K, Wiley E, Katzenellenbogen B. (2009). A breast cancer gene signature associated with high expression of 14-3-3z predicts poor clinical outcome on endocrine therapy. Proc Am Assoc Cancer Res Annu Meet 2: 2854.
7. Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA et al. (2008). Estrogen receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol 22: 1032-1043. (Pubitemid 351629605)
8. Costa RH. (2005). FoxM1 dances with mitosis. Nat Cell Biol 7: 108-110. (Pubitemid 40268125)
9. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. (2006). Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66: 3903-3911.
10. Croce CM. (2009). Causes and consequences of microRNA dysregula-tion in cancer. Nat Rev Genet 10: 704-714.
11. Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, Tobias JW et al. (2008). A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci USA 105: 3333-3338. (Pubitemid 351723553)
12. Dunn BK, Ford LG. (2001). From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J 7: 144-157. (Pubitemid 32619775)
13. EBCTCG (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
14. Filipowicz W, Bhattacharyya SN, Sonenberg N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114.
15. Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET et al. (2006). Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66: 7334-7340. (Pubitemid 44197716)
16. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. (2004). Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64: 1522-1533. (Pubitemid 38235626)
17. Green KA, Carroll JS. (2007). Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev 7: 713-722. (Pubitemid 47327416)
18. Guo H, Ingolia NT, Weissman JS, Bartel DP. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
19. Harfe BD. (2005). MicroRNAs in vertebrate development. Curr Opin Genet Dev 15: 410-415. (Pubitemid 40982092)
20. Herman ME, Katzenellenbogen BS. (1996). Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Mol Biol 59: 121-134. (Pubitemid 27036264)
21. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. (1995). Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529.
22. Katzenellenbogen BS, Katzenellenbogen JA. (2002). Biomedicine. Defining the 'S' in SERMs. Science 295: 2380-2381.
23. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. (1996). Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol Endocrinol 10: 119-131. (Pubitemid 26042544)
24. Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L et al. (2008). Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 105: 162-167.
25. Lowery AJ, Miller N, McNeill RE, Kerin MJ. (2008). MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 14: 360-365. (Pubitemid 351226101)
26. Masaki S, Ohtsuka R, Abe Y, Muta K, Umemura T. (2007). Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun 364: 509-514. (Pubitemid 350026496)
27. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S et al. (2008). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68: 826-833. (Pubitemid 351206760)
28. McPherson RA, Harding A, Roy S, Lane A, Hancock JF. (1999). Interactions of c-Raf-1 with phosphatidylserine and 14-3-3. Oncogene 18: 3862-3869. (Pubitemid 29358564)
29. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J et al. (2009). 14-3-3 {zeta} overexpression defines high risk for breast. Cancer Res 69: 3425-3432.
30. Oksvold MP, Huitfeldt HS, Langdon WY. (2004). Identification of 14-3-3[zeta] as an EGF receptor interacting protein. FEBS Lett 569: 207-210. (Pubitemid 38844619)
31. Osborne CK. (1998). Tamoxifen in the treatment of breast cancer. New Engl J Med 339: 1609-1618. (Pubitemid 28536137)
32. Patrick DM, Zhang CC, Tao Y, Yao H, Qi X, Schwartz RJ et al. (2010). Defective erythroid differentiation in miR-. Genes Dev 24: 1614-1619.
33. Riccardi C, Nicoletti I. (2006). Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protocols 1: 1458-1461.
34. Shan G, Li Y, Zhang J, Li W, Szulwach KE, Duan R et al. (2008). A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 26: 933-940.
35. Shang Y, Brown M. (2002). Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468. (Pubitemid 34270263)
36. Tzivion G, Gupta VS, Kaplun L, Balan V. (2006). 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 16: 203-213. (Pubitemid 43810260)
37. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et al. (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741.
38. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et al. (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 3: 696-706.
39. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN et al. (2009). ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. Embo J 28: 1418-1428.
40. Williams AE, Perry MM, Moschos SA, Lindsay MA. (2007). microRNA expression in the aging mouse lung. BMC Genomics 8: 172.
41. Yang JS, Maurin T, Robine N, Rasmussen KD, Jeffrey KL, Chandwani R et al. (2010). Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci USA 107: 15163-15168.
42. Yu D, Dos Santos CO, Zhao G, Jiang J, Amigo JD, Khandros E et al. (2010). miR-451 protects against erythroid oxidant stress by repressing 14-3-3 {zeta}. Genes Dev 24: 1620-1633.